Skip to contentI
Interpace Biosciences, Inc.
I
IDXGInterpace Biosciences, Inc. Q4 2014 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$28.83M$28.83Mderived−10.2% vs Q4 2013 Net Income-$8.04M-$8.04MderivedN/M vs Q4 2013 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Interpace Biosciences, Inc. · CIK 1054102 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived-$13,961,000N/M Operating Incomederived-$13,148,000N/M Operating Cash Flowderived-$8,412,000N/M Free Cash Flowderived-$9,965,000N/M Margins · derivedGross margin-48.4%−59.3 pt vs Q4 2013
Operating margin-45.6%−43.1 pt vs Q4 2013
Net margin-27.9%−16.5 pt vs Q4 2013
ended Dec 31, 2014 · filed Mar 5, 2015 · 64 d after period end